Product Images Enoxaparin Sodium

This appears to be a table with different subgroups based on characteristics such as sex, age, infarct location, diabetes, prior MI, fibrinolytic agent, time to treatment, and PCl in 30 days. The table also includes the number of patients in each subgroup, the percentage of patients with UFH and enoxaparin, the risk reduction percentage for each subgroup, and the overall relative risk. The last line of the table suggests that Enoxaparin is better than UFH.*

This appears to be a table of data related to a medical study of a drug called Enoxaparin. It includes two instances of the Log-Rank Test being performed with corresponding P-values of "p<0.0001" and "p=0.0111". Additionally, there is a graph or chart with 6 time points spanning 360 days, which seems to be tracking the occurrence of death or myocardial re-infarction. No additional information on the study or its purpose is provided.*

This is a label for the drug Enoxaparin Sodium Injection, USP. It is a multi-dose vial with 1x3 ml that is intended for subcutaneous or intravenous injection. Each 0.1 ml is made up of 10mg of enoxaparin sodium, water for injection, and 1.5 mg of benzyl alcohol. The package contains the dosage information and directions for use. It has a warning that it should be kept away from children, and it should not be stored for more than 28 days after the first use. The container closure is not made with natural rubber latex. It is manufactured by Meitheal Pharmaceuticals in China and distributed in the USA.*

This is a description of a medication called Enoxaparin Sodium Injection, USP made by Meitheal Pharmaceuticals. It is used for subcutaneous or intravenous injection for patients. The medication comes in vials that contain 300mg of the medication per 3mL. The dosage instructions are not clearly mentioned in the text.*